TriMas Corporation

TriMas Corporation (TRS) Market Cap

TriMas Corporation has a market capitalization of .

No quote data available.

CEO: Thomas J. Snyder

Sector: Consumer Cyclical

Industry: Packaging & Containers

IPO Date: 2007-05-18

Website: https://trimas.com

TriMas Corporation (TRS) - Company Information

Market Cap: -|Sector: Consumer Cyclical

Company Profile

TriMas Corporation (TRS) is a global industrial company focused on the engineering, manufacturing, and distribution of a diverse range of products spanning consumer, aerospace, and industrial markets. Its operations are structured into three primary segments: Packaging, Aerospace, and Specialty Products. The Packaging division delivers numerous solutions for dispensing and sealing. This includes a variety of pumps and sprayers—such as those for foam, sanitizers, lotions, beverages, perfumes, and nasal applications—along with plastic and steel caps and closures like food lids, flip-tops, child-resistant options, drum/pail seals, and flexible spouts. Other offerings encompass polymeric jars, integrated dispensers, bag-in-box products, aseptic and industrial closures, as well as custom and standard injection-molded components. This segment's well-known brands include Rieke, Taplast, Affaba & Ferrari, Stolz, Omega, and Rapak. The Aerospace segment focuses on highly engineered components for the aviation industry. Its product portfolio features fasteners (such as collars, blind bolts, and rivets), ducting, connectors for air management systems, and a range of machined parts. These are provided to original equipment manufacturers (OEMs), supply chain partners, MRO (maintenance, repair, and overhaul) providers, primary suppliers, and for use in military and defense aviation applications. Prominent brands within this division include Monogram Aerospace Fasteners, Allfast Fastening Systems, Mac Fasteners, TFI Aerospace, RSA Engineered Products, and Martinic Engineering. The Specialty Products division offers two main product lines. Under the Norris Cylinder brand, it supplies robust steel cylinders designed for the secure conveyance, containment, and controlled release of pressurized gases. Furthermore, through its Arrow brand, it manufactures natural gas-powered wellhead engines, compressors, and their corresponding spare parts, essential for oil and natural gas extraction operations, alongside broader industrial and commercial applications. This segment also provides spare parts for a variety of industrial engines. Distribution of TriMas's offerings is handled by its in-house sales force, independent third-party agents, and a network of authorized distributors. TriMas Corporation, founded in 1986, is based in Bloomfield Hills, Michigan.

Analyst Sentiment

92%
Strong Buy

From 2 Active Polls

1Y Forecast: $38.00

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$38

Median

$38

High Bound

$38

Average

$38

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$38.00
▼ -4.83% Upside
Low Target
$38.00
-5% Risk
Median Target
$38.00
-5% Mid
High Target
$38.00
-5% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 TRIMAS CORP (TRS) — Investment Overview

🧩 Business Model Overview

TriMas is an engineered-products manufacturer and supplier serving a range of industrial and end-market customers. The business model centers on designing, producing, and qualifying specialty components that get incorporated into customers’ finished products (rather than selling generic commodities). Value creation comes from (1) translating customer application requirements into manufacturable designs, (2) maintaining stable quality at scale, and (3) supporting customers through the qualification cycle and ongoing production volumes.

Customer stickiness typically arises because TriMas’ offerings are embedded in customers’ product engineering and supply chains, where approvals, performance specifications, and documentation requirements limit frequent substitution.

💰 Revenue Streams & Monetisation Model

TriMas monetizes through a mix of contract-like program revenue and ongoing production shipments tied to customer demand. Pricing generally reflects a combination of:

  • Unit economics from manufacturing execution (yield, labor productivity, throughput).
  • Pass-through and mix (ability to manage input cost volatility and capitalize on favorable product mix).
  • Application-specific differentiation (engineering-led components that command premiums versus commodity alternatives).

While revenue can be cyclical with end-market production levels, the company’s engineered positioning supports comparatively higher gross margin quality than purely commodity suppliers, assuming execution and customer retention remain intact.

🧠 Competitive Advantages & Market Positioning

TriMas’ moat is best framed as switching costs and manufacturing/qualification capability, reinforced by cost advantages from scale and process know-how in specialized product categories. Competitors can introduce new products, but displacing an approved supplier often requires technical requalification, tooling/validation, and supply chain redesign—items that slow customer switching and support retention.

  • Switching costs (qualification + documentation + performance requirements): Once designs are specified and performance standards are met, requalification risk and administrative overhead create friction for buyers.
  • Manufacturing competence: Specialized processes, quality systems, and repeatable output reduce customer risk.
  • Intangible asset accumulation: Long-term relationships and application-specific engineering know-how build a track record that is difficult to replicate quickly.

COMPETITIVE BENCHMARKING (Primary competitors)

  • AptarGroup: Strong position in engineered drug delivery and dosage systems. Aptar often emphasizes deep end-market specialization in specific healthcare packaging/delivery categories; TriMas competes where engineering-enabled solutions and customer qualification matter, but with a broader engineered-products orientation.
  • Berry Global: Larger scale across packaging plastics and related products. Berry’s advantage is breadth and scale in packaging; TriMas typically emphasizes engineered, application-specific components where technical requirements and qualification cycles create stickiness.
  • RPC Group (and similar specialty packaging manufacturers): Focus on engineered rigid packaging and components. RPC competes on design capability and customer engagement; TriMas differentiates through a portfolio mix and manufacturing execution suited to customers seeking qualified engineered suppliers rather than purely standardized offerings.

🚀 Multi-Year Growth Drivers

Key growth drivers over a 5–10 year horizon are primarily structural rather than dependent on near-term market timing:

  • Outsourcing of engineered components: Customers increasingly seek specialized suppliers that can manage design-to-production execution.
  • Higher specification requirements: Quality systems, performance standards, and documentation requirements increase the value of qualified suppliers and raise barriers to entry.
  • Product mix shift toward engineered differentiation: Application complexity and regulatory/consumer performance expectations tend to favor engineered solutions over commodity inputs.
  • Supply-chain resilience and geographic preference: Buyers often favor established suppliers capable of consistent production and responsive sourcing, supporting demand durability for qualified providers.
  • Process and efficiency improvements: Continuous manufacturing optimization can expand operating margins even in mature end markets, provided input cost and utilization are managed.

⚠ Risk Factors to Monitor

  • End-market cyclicality: Engineered component demand typically tracks industrial production and customer build schedules.
  • Input cost volatility: Resins, metals, energy, and logistics can pressure margins if contracts or pricing power do not offset costs.
  • Customer concentration and program timing: Revenue can be influenced by customer sourcing strategies, launch timing, and volume ramps.
  • Execution risk in capacity and integrations: Manufacturing expansions, process changes, and portfolio reshaping require disciplined capital allocation and operational management.
  • Regulatory and compliance requirements: For healthcare-adjacent applications, adherence to quality and documentation standards is essential and failure can impair customer relationships.

📊 Valuation & Market View

Equity valuation for engineered industrial and packaging-adjacent manufacturers commonly anchors to EV/EBITDA and earnings power, with investors underwriting:

  • Margin durability (gross margin quality, operating leverage, and cost pass-through ability).
  • Free cash flow conversion (working capital discipline and capex efficiency).
  • Customer retention and program stability (evidence of sustained qualification and repeat ordering).
  • Credible growth pathways (new program wins, mix shift, and efficiency initiatives).

Because TriMas operates across multiple engineered product categories, market participants often apply a discount or premium based on perceived segment synergy, end-market diversification, and confidence in sustainable execution.

🔍 Investment Takeaway

TriMas is best viewed as an engineered supplier where qualification-driven switching costs, manufacturing execution capability, and application-specific differentiation support durable customer relationships. The long-term investment case rests on the ability to maintain margin quality through input-cycle volatility, win and retain engineered programs, and convert operational improvements into steadier free cash flow—while managing the inherent cyclicality of served end markets.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"TRS reported Q2’26 revenue of $174.6M (QoQ +3.7%, YoY -36.5%) and net income of -$0.8M (vs. Q1’26 net income of $800.8M, YoY -$8.6M vs. Q2’25 net income of $16.7M). Gross margin was 21.1% (roughly flat QoQ; down vs. Q2’25 24.0%) while operating margin contracted sharply to 3.9% from 6.5% QoQ and 9.9% YoY—signaling margin pressure and/or non-recurring items. Balance sheet strength remains a key positive: cash & equivalents were $1.24B and total assets were $2.25B at 6/30/26, with equity at $1.44B and very low total debt ($40.9M). Liquidity is therefore high even though profitability swung negative in the latest quarter. Cash flow improved materially: operating cash flow was $137.1M and free cash flow was $129.2M in Q2’26, with cash increasing by $93.0M QoQ. However, Q1’26 cash flows were heavily impacted by large acquisition/investing line items, so sustainability of these operating gains should be monitored. Shareholder returns appear strong on momentum: the stock price is up +88.5% over 1 year (dividend yield ~0.09%), which should support a higher total-return score despite current earnings volatility. Analyst consensus price target is $38 (target/last ~0.99)."

Revenue Growth

Neutral

Q2’26 revenue of $174.6M rose QoQ to $168.3M (+3.7%) but fell YoY from $274.8M (-36.5%), indicating a clear deceleration.

Profitability

Neutral

Net income swung to -$0.8M from +$800.8M QoQ and deteriorated YoY (-$16.7M to -$0.8M; -$8.6M worse). Margins contracted: operating margin fell to 3.9% (from 6.5% QoQ) and down from 9.9% YoY; gross margin also slipped vs. Q2’25.

Cash Flow Quality

Neutral

Despite negative earnings, Q2’26 operating cash flow was strong at $137.1M and free cash flow was $129.2M. Dividend outflows were modest (dividends paid -$1.46M) and coverage by operating cash flow appears adequate, though prior-quarter investing/acquisition effects were significant.

Leverage & Balance Sheet

Strong

Major balance-sheet strength for TRS: cash & equivalents of $1.24B, total assets $2.25B, equity $1.44B, and very low total debt ($40.9M; net debt -$1.20B). Resilience is high.

Shareholder Returns

Good

Total shareholder return likely supported by strong momentum: 1-year price change +88.5%. Dividend yield is small (~0.09%), so the bulk of returns comes from price appreciation.

Analyst Sentiment & Valuation

Neutral

Consensus price target is $38 versus current price $38.24 (near fair value). With recent earnings volatility, upside may depend on margin stabilization and continued cash generation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

TriMas delivered a margin-led turnaround in Q2 2026, expanding adjusted operating margin 180 bps to 8.5% and lifting adjusted EPS to $0.52 (from $0.20). Packaging drove much of the improvement: net sales were flat, but adjusted operating margin rose 50 bps to 14.8% as cost-reduction actions and operational excellence progressed. The quarter also highlighted near-term earnings noise—resin cost under-recovery pressured margins by ~100 bps, while Specialty Products’ margin fell to 2.2% due to ramp-up inefficiencies (temporary labor/overtime/overhead). Management raised full-year adjusted EPS guidance to $1.60-$1.70 (lower end +$0.10) and reiterated full-year sales growth of 3%-6%, with operating profit margin improvement of >300 bps. The outlook relies on (1) Atkins consolidation benefits in 2H26, (2) cumulative price-cost recovery in 3Q-4Q, and (3) continued automation/right-sizing to restore Specialty margins.

AI IconGrowth Catalysts

  • Packaging: cost-reduction actions and operational excellence driving margin expansion; Atkins Arkansas closure positioning for additional cost savings/margin benefits in 2H26
  • Packaging: price-cost recovery expected to flip net positive in 3Q as resin cost over/under-recovery normalizes on a cumulative basis in 3Q-4Q
  • Specialty Products (Norris Cylinder): continued market-share gains and healthy order activity supporting stronger demand backdrop
  • Norris Cylinder: Made in USA designation supporting higher full-year Specialty Products growth

Business Development

  • Strategic Investment Committee and management actively evaluating acquisitions in Packaging and Life Sciences; focus on higher-quality companies that elevate products/geography/positioning and strengthen customer relationships and IP (no named targets disclosed)
  • Third-party advisors engaged in evaluating potential deals (no partners/customers named)

AI IconFinancial Highlights

  • Consolidated net sales up 1.6% YoY to $174.6M; organic sales essentially flat
  • Adjusted operating profit up 29% to $14.9M; adjusted operating margin expanded 180 bps to 8.5%
  • Adjusted EPS increased to $0.52 vs $0.20 prior year (drivers: stronger ops, higher interest income from invested proceeds, share repurchase benefits; higher tax rate partially offset)
  • YTD: net sales up 5.8% to $342.9M; organic growth 3.4%; adjusted EPS more than doubled to $0.75
  • Packaging: net sales essentially flat at $143M; adjusted operating profit up 3.7% to $21.2M; margin expanded 50 bps to 14.8%
  • Packaging price-cost: resin costs under-recovered in Q2 pressuring margins by ~100 bps; expect recovery on cumulative basis between 3Q-4Q
  • Packaging tariffs: viewed generally neutral over time; no significant effects in Q2 from court rulings or changes in tariff levels
  • Specialty Products: net sales +10.2% YoY to nearly $32M; operating margin declined to 2.2% from 4.4% due to ramp-up inefficiencies and higher temporary labor/overtime/overhead; operating profit $0.7M vs $1.3M prior year
  • Specialty Products outlook: full-year sales growth raised to 6% to 9% (from 3% to 6%); operating margins expected 6% to 8% (reflecting higher Q2 costs)
  • Total company outlook raised EPS guidance lower end by $0.10 to $1.60-$1.70 (from $1.50-$1.70); assumes no significant redeployment of remaining Aerospace proceeds

AI IconCapital Funding

  • Post-Aerospace divestiture: share repurchases of $175M through end of Q2 2026; repurchased 5M+ shares since November; shares outstanding ~35.9M at quarter-end
  • Remaining share authorization: $76M available under current authorization
  • Balance sheet: >$1.2B cash; net cash position of $846M
  • Income taxes on transaction gain: began funding; paid $30M in Q2; expect half remaining in 3Q and rest split between 4Q and 1Q27
  • Interest-bearing investments average yield: 3.7%
  • Debt: $400M senior notes due 2029 at 4.25% with no near-term maturities
  • Free cash flow: use of ~$12.9M in Q2 2026 vs source of $7.7M prior year (timing/collection effects; higher June sales; Middle East event uncertainty earlier in quarter)

AI IconStrategy & Ops

  • Packaging leadership team strengthened: Gil Arrow appointed SVP Sales & Marketing; Angel Fernandez Carbonell appointed VP Global Operations
  • Strategic planning framework implemented initially across TriMas Packaging, later deployed within Norris Cylinder to align priorities with clear ownership, measurable objectives, and timelines
  • One TriMas initiative: integration of legacy packaging brands under unified TriMas Packaging identity to simplify customer experience and align commercial execution
  • Atkins facility closure and consolidation: closed/consolidated Atkins, Arkansas facility; expecting additional 2H26 cost savings/margin benefits
  • Specialty Products operational response: right-sizing labor force, overhead spending, and production scheduling to match machine capacity; evaluating further automation/process improvements
  • Cost-reduction program: previously announced actions totaling $10.5M in 2026 and $16M annually remain on track

AI IconMarket Outlook

  • Total company: full-year sales growth expected 3% to 6%; operating profit margin improvement >300 bps vs 2025
  • Total company adjusted EPS guidance: raised lower end by $0.10 to $1.60-$1.70 (upper end unchanged); guidance reflects stronger-than-expected interest income; no significant redeployment of remaining Aerospace proceeds assumed
  • Packaging: full-year sales growth expected 3% to 6%; operating margins expected 14% to 15%; sequential margin expansion expected in 3Q as price-cost recovery flips net positive
  • Specialty Products: raised full-year sales growth to 6% to 9%; operating margins expected 6% to 8%

AI IconRisks & Headwinds

  • Packaging: resin costs escalated mid-to-late 1Q through 2Q; Q2 under-recovery pressured margins by ~100 bps (recovery depends on future market volatility)
  • Packaging end-market demand mixed; organic essentially flat YoY with softer beauty/personal care and food/bev applications partly due to Atkins facility consolidation timing
  • Specialty Products: profitability impacted by ramp-up challenges (temporary labor, overtime, overhead, manufacturing inefficiencies) despite healthy demand; right-sizing/automation efforts needed for margin normalization
  • Macro/geopolitical/tariff uncertainty: ongoing monitoring; tariffs viewed neutral over time but replacement tariffs/policy changes remain potential exposure
  • FCF timing risk: Q2 cash use influenced by sales/collection timing and Middle East-related uncertainty earlier in quarter

Q&A: Analyst Interest

  • Beauty/Personal Care and Food & Beverage ramp timing: Management said food & beverage softness was largely a one-time Atkins relocation/consolidation pause; assets relocated and ramp work continues, with demand viewed as good. Beauty/personal care expected a return to a more normal back-half pattern after a lumpier Q2.
  • Packaging guidance build (YOY vs sequential) and organic drivers: Management clarified guidance is primarily year-over-year, supported by easier comps from a stronger 1H25 and by expecting currency tailwind replacement with organic growth in end markets. They cited that Q2 downticks in beauty/food were not expected to persist into the back half.
  • Sequencing of additional operational improvement opportunities (beyond $10.5M cost actions): Management indicated more items will be actioned in 2H26, with benefits expected in timing through Q3-Q4. They also emphasized constraints of personnel/timing, and linked further pipeline to automation and cost-base modernization in both Norris and Packaging.

Sentiment: MIXED

Note: This summary was synthesized by AI from the TRS Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — TriMas Corporation (TRS) Financial Profile